SG10201602044WA - Methods For Treating HCV - Google Patents

Methods For Treating HCV

Info

Publication number
SG10201602044WA
SG10201602044WA SG10201602044WA SG10201602044WA SG10201602044WA SG 10201602044W A SG10201602044W A SG 10201602044WA SG 10201602044W A SG10201602044W A SG 10201602044WA SG 10201602044W A SG10201602044W A SG 10201602044WA SG 10201602044W A SG10201602044W A SG 10201602044WA
Authority
SG
Singapore
Prior art keywords
methods
treating hcv
hcv
treating
Prior art date
Application number
SG10201602044WA
Other languages
English (en)
Inventor
Adrian S Ray
William J Watkins
John O Link
David W Oldach
Iv William E Delaney
Original Assignee
Gilead Pharmassett Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46970425&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201602044W(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Pharmassett Llc filed Critical Gilead Pharmassett Llc
Publication of SG10201602044WA publication Critical patent/SG10201602044WA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Treating Waste Gases (AREA)
  • Exhaust Gas After Treatment (AREA)
SG10201602044WA 2011-09-16 2012-09-14 Methods For Treating HCV SG10201602044WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161535885P 2011-09-16 2011-09-16
US201161561753P 2011-11-18 2011-11-18

Publications (1)

Publication Number Publication Date
SG10201602044WA true SG10201602044WA (en) 2016-04-28

Family

ID=46970425

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201400664WA SG11201400664WA (en) 2011-09-16 2012-09-14 Methods for treating hcv
SG10201602044WA SG10201602044WA (en) 2011-09-16 2012-09-14 Methods For Treating HCV

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201400664WA SG11201400664WA (en) 2011-09-16 2012-09-14 Methods for treating hcv

Country Status (36)

Country Link
US (3) US9393256B2 (pt)
EP (1) EP2709613B2 (pt)
JP (2) JP6073897B2 (pt)
KR (2) KR101991298B1 (pt)
CN (2) CN106166160A (pt)
AP (1) AP2014007575A0 (pt)
AU (1) AU2012308295B2 (pt)
BR (1) BR112014006324B8 (pt)
CA (1) CA2840242C (pt)
CL (1) CL2014000630A1 (pt)
CO (1) CO6930366A2 (pt)
CR (1) CR20140177A (pt)
CY (1) CY1119896T1 (pt)
DE (2) DE202012013382U1 (pt)
DK (1) DK2709613T4 (pt)
EA (1) EA026667B9 (pt)
EC (1) ECSP14013312A (pt)
ES (1) ES2659216T5 (pt)
HK (1) HK1231378A1 (pt)
HR (1) HRP20180237T4 (pt)
HU (1) HUE036588T2 (pt)
IL (1) IL231515A (pt)
LT (1) LT2709613T (pt)
MD (1) MD4589C1 (pt)
ME (1) ME03009B (pt)
MX (2) MX354958B (pt)
NZ (1) NZ623396A (pt)
PE (1) PE20141056A1 (pt)
PL (1) PL2709613T5 (pt)
PT (1) PT2709613T (pt)
RS (1) RS56975B1 (pt)
SG (2) SG11201400664WA (pt)
SI (1) SI2709613T2 (pt)
TR (1) TR201802537T4 (pt)
UA (1) UA116087C2 (pt)
WO (1) WO2013040492A2 (pt)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1633766T (pt) 2003-05-30 2019-06-04 Gilead Pharmasset Llc Análogos de nucleósido fluorado modificado
TW201639852A (zh) 2008-12-09 2016-11-16 吉李德科學股份有限公司 用於製備可用作類鐸受體調節劑之化合物的中間體化合物
DK2430014T3 (en) 2009-05-13 2015-11-30 Gilead Pharmasset Llc Anti-viral compounds
SI2480559T1 (sl) 2009-09-21 2013-10-30 Gilead Sciences, Inc. Postopki in intermediati za pripravo 1'-ciano-karbanukleozidnih analogov
ES2524356T3 (es) 2010-07-22 2014-12-05 Gilead Sciences, Inc. Métodos y compuestos para tratar infecciones provocadas por virus Paramyxoviridae
NZ613370A (en) 2010-12-20 2015-05-29 Gilead Sciences Inc Combinations for treating hcv
SI2709613T2 (sl) 2011-09-16 2020-12-31 Gilead Pharmasset LLC c/o Gilead Sciences, Inc. Postopki za zdravljenje HCV
GB2506086A (en) 2011-10-21 2014-03-19 Abbvie Inc Methods for treating HCV comprising at least two direct acting antiviral agent, ribavirin but not interferon
CA2811250C (en) * 2011-10-21 2015-08-11 Abbvie Inc. Methods for treating hcv
AU2015100283B4 (en) * 2011-10-21 2015-06-18 Abbvie Ireland Unlimited Company Methods for treating HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
AU2015200715A1 (en) * 2011-10-21 2015-03-05 Abbvie Ireland Unlimited Company Methods for treating HCV
SG11201506021XA (en) 2013-01-31 2015-08-28 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
WO2014185995A1 (en) * 2013-05-16 2014-11-20 Gilead Pharmasset Llc Hepatitis c treatments with sofosbuvir
CN104211565A (zh) * 2013-05-31 2014-12-17 浙江九洲药业股份有限公司 一种抗丙型肝炎药物中间体的制备方法
MX2016002185A (es) 2013-08-27 2016-06-06 Gilead Pharmasset Llc Formulacion combinada de dos compuestos antivirales.
MX2017000026A (es) 2014-07-11 2017-05-01 Gilead Sciences Inc Moduladores de receptores tipo toll para el tratamiento de virus de inmunodeficiencia humana (vih).
CN104130302B (zh) * 2014-08-08 2017-02-15 乳源东阳光药业有限公司 一种核苷药物的晶型及其制备方法
SI3194401T1 (sl) 2014-09-16 2020-12-31 Gilead Sciences, Inc. Trdne oblike modulatorja toličnega receptorja
TWI687432B (zh) 2014-10-29 2020-03-11 美商基利科學股份有限公司 絲狀病毒科病毒感染之治療
RS62434B1 (sr) 2014-12-26 2021-11-30 Univ Emory Antivirusni n4-hidroksicitidin derivati
CN106138080A (zh) * 2015-04-03 2016-11-23 南开大学 核苷类化合物在制备治疗丙型肝炎病毒(hcv)感染疾病药物的应用
CN106146585B (zh) * 2015-04-10 2019-05-28 正大天晴药业集团股份有限公司 氘修饰的脲苷衍生物
HUE058737T2 (hu) * 2015-09-16 2022-09-28 Gilead Sciences Inc Eljárások arenaviridae vírusok okozta fertõzések kezelésére
US11192914B2 (en) 2016-04-28 2021-12-07 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto
WO2017195147A1 (en) * 2016-05-12 2017-11-16 Lupin Limited Process for the preparation of ledipasvir and intermediates thereof
CN105968040B (zh) * 2016-06-29 2019-02-05 爱斯特（成都）生物制药股份有限公司 一种雷迪帕韦中间体的制备方法
CN106432197B (zh) * 2016-09-07 2019-12-10 上海众强药业有限公司 一种雷迪帕韦中间体单对甲苯磺酸盐、其晶型及其制备方法
CN116036112A (zh) 2017-03-14 2023-05-02 吉利德科学公司 治疗猫冠状病毒感染的方法
ES2938859T3 (es) 2017-05-01 2023-04-17 Gilead Sciences Inc Una forma cristalina de (S)-2-etilbutilo 2-(((S)-(((2R,3S,4R,5R)-5-(4-aminopirrolo[2,1-f][1,2,4]triazin-7-il)-5-ciano-3,4-dihidroxitetrahidrofuran-2-il)metoxi)(fenoxi)fosforil)amino)propanoato
CN117982682A (zh) 2017-07-11 2024-05-07 吉利德科学公司 用于治疗病毒感染的包含rna聚合酶抑制剂和环糊精的组合物
CN107629099B (zh) * 2017-07-26 2020-05-26 江苏科本药业有限公司 一种索非布韦中间体的制备工艺
EP3684374A4 (en) * 2017-09-21 2021-06-16 Riboscience LLC 4'-FLUORO-2'-METHYL SUBSTITUTE NUCLEOSIDE DERIVATIVES USED AS HCV RNA REPLICATION INHIBITORS
KR102626210B1 (ko) 2017-12-07 2024-01-18 에모리 유니버시티 N4-하이드록시사이티딘 및 유도체 및 이와 관련된 항-바이러스 용도
CN109651472B (zh) * 2018-12-29 2020-08-18 湖南千金湘江药业股份有限公司 合成索非布韦关键中间体的方法
CN110531023B (zh) * 2019-10-08 2024-06-14 安徽理工大学 一种薄层色谱分析仪
CN111990544A (zh) * 2019-10-16 2020-11-27 长沙绿叶生物科技有限公司 一种用于阻断和干扰非洲猪瘟病毒与猪的特异受体结合的生物饲料及其应用
JP2023512656A (ja) 2020-01-27 2023-03-28 ギリアード サイエンシーズ， インコーポレイテッド ＳＡＲＳ ＣｏＶ－２感染を治療するための方法
TWI794742B (zh) 2020-02-18 2023-03-01 美商基利科學股份有限公司 抗病毒化合物
US12030903B2 (en) 2020-02-18 2024-07-09 Gilead Sciences, Inc. Antiviral compounds
TWI775313B (zh) 2020-02-18 2022-08-21 美商基利科學股份有限公司 抗病毒化合物
CA3169340A1 (en) 2020-03-12 2021-09-16 Pavel R. Badalov Methods of preparing 1'-cyano nucleosides
CA3172483A1 (en) 2020-04-06 2021-10-14 Scott Ellis Inhalation formulations of 1'-cyano substituted carbanucleoside analogs
US11975012B2 (en) 2020-05-29 2024-05-07 Gilead Sciences, Inc. Remdesivir treatment methods
AU2021296841A1 (en) 2020-06-24 2023-02-16 Gilead Sciences, Inc. 1'-cyano nucleoside analogs and uses thereof
PT4204421T (pt) 2020-08-27 2024-06-25 Gilead Sciences Inc Compostos e métodos para o tratamento de infeções virais
CA3216162A1 (en) 2021-04-16 2022-10-20 Gilead Sciences, Inc. Methods of preparing carbanucleosides using amides
EP4341266A1 (en) 2021-05-21 2024-03-27 Gilead Sciences, Inc. Pentacyclic derivatives as zika virus inhibitors
EP4320128A1 (en) 2022-03-02 2024-02-14 Gilead Sciences, Inc. Compounds and methods for treatment of viral infections

Family Cites Families (327)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3798209A (en) 1971-06-01 1974-03-19 Icn Pharmaceuticals 1,2,4-triazole nucleosides
USRE29835E (en) 1971-06-01 1978-11-14 Icn Pharmaceuticals 1,2,4-Triazole nucleosides
JPS5238939A (en) 1975-09-23 1977-03-25 Nippon Telegr & Teleph Corp <Ntt> Optical coupler
US4614719A (en) 1982-04-30 1986-09-30 Yamasa Shoyu Kabushiki Kaisha Process for producing ribavirin
US5223263A (en) 1988-07-07 1993-06-29 Vical, Inc. Liponucleotide-containing liposomes
US5194654A (en) 1989-11-22 1993-03-16 Vical, Inc. Lipid derivatives of phosphonoacids for liposomal incorporation and method of use
US5463092A (en) 1989-11-22 1995-10-31 Vestar, Inc. Lipid derivatives of phosphonacids for liposomal incorporation and method of use
US5026687A (en) 1990-01-03 1991-06-25 The United States Of America As Represented By The Department Of Health And Human Services Treatment of human retroviral infections with 2',3'-dideoxyinosine alone and in combination with other antiviral compounds
US5210015A (en) 1990-08-06 1993-05-11 Hoffman-La Roche Inc. Homogeneous assay system using the nuclease activity of a nucleic acid polymerase
WO1993000910A1 (en) 1991-07-12 1993-01-21 Vical, Inc. Antiviral liponucleosides: treatment of hepatitis b
US5538848A (en) 1994-11-16 1996-07-23 Applied Biosystems Division, Perkin-Elmer Corp. Method for detecting nucleic acid amplification using self-quenching fluorescence probe
US5703058A (en) 1995-01-27 1997-12-30 Emory University Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
US6391859B1 (en) 1995-01-27 2002-05-21 Emory University [5-Carboxamido or 5-fluoro]-[2′,3′-unsaturated or 3′-modified]-pyrimidine nucleosides
EP0806956B1 (de) 1995-02-01 2002-08-28 RESprotect GmbH Verwendung von 5' substituierten nukleosiden zur hemmung von resistenzbildung bei der zytostatikabehandlung
GB9505025D0 (en) 1995-03-13 1995-05-03 Medical Res Council Chemical compounds
DE19514523A1 (de) 1995-04-12 1996-10-17 Schering Ag Neue Cytosin- und Cytidinderivate
WO2005121370A2 (en) 2004-06-03 2005-12-22 Isis Pharmaceuticals, Inc. Oligomeric compounds that facilitate risc loading
US5858389A (en) 1996-08-28 1999-01-12 Shaker H. Elsherbini Squalene is an antiviral compound for treating hepatitis C virus carriers
CN1233254A (zh) 1996-10-16 1999-10-27 Icn药品公司 嘌呤l－核苷、其类似物及其用途
PT1027359E (pt) 1996-10-16 2003-09-30 Ribapharm Inc L-nucleosideos monociclicos analogos e suas utilizacoes
US6509320B1 (en) 1996-10-16 2003-01-21 Icn Pharmaceuticals, Inc. Purine L-nucleosides, analogs and uses thereof
DE69801970T2 (de) 1997-09-21 2002-06-13 Schering Corp., Kenilworth Kombinationstherapie zur Entfernung von nachweisbarer HCV-RNS in Patienten mit chronischer Hepatitis C-Infektion
US6201262B1 (en) 1997-10-07 2001-03-13 Cree, Inc. Group III nitride photonic devices on silicon carbide substrates with conductive buffer interlay structure
US6703374B1 (en) 1997-10-30 2004-03-09 The United States Of America As Represented By The Department Of Health And Human Services Nucleosides for imaging and treatment applications
PT1045897E (pt) 1998-01-23 2002-07-31 Newbiotics Inc Agentes terapeuticos por catalise enzimatica
US7462605B2 (en) 1998-01-23 2008-12-09 Celmed Oncology (Usa), Inc. Phosphoramidate compounds and methods of use
MXPA00008348A (es) 1998-02-25 2005-07-15 Univ Emory 2-fluronucleosidos.
US6787305B1 (en) 1998-03-13 2004-09-07 Invitrogen Corporation Compositions and methods for enhanced synthesis of nucleic acid molecules
US6475985B1 (en) 1998-03-27 2002-11-05 Regents Of The University Of Minnesota Nucleosides with antiviral and anticancer activity
JP5281726B2 (ja) 1998-05-15 2013-09-04 メルク・シャープ・アンド・ドーム・コーポレーション 慢性Ｃ型肝炎感染を有する、抗ウイルス処置を受けていない患者における、リバビリンおよびインターフェロンαを含む併用療法
PL192364B1 (pl) 1998-06-08 2006-10-31 Hoffmann La Roche Zastosowanie koniugatu PEG-IFN-α 2A w połączeniu z rybawiryną
GB9816358D0 (en) 1998-07-27 1998-09-23 Angeletti P Ist Richerche Bio Enzyme inhibitors
CA2340156C (en) 1998-08-10 2007-10-23 Novirio Pharmaceuticals Limited .beta.-l-2'-deoxy-nucleosides for the treatment of hepatitis b
GB9821058D0 (en) 1998-09-28 1998-11-18 Univ Cardiff Chemical compound
WO2000037110A2 (en) 1998-12-18 2000-06-29 Schering Corporation Ribavirin-pegylated interferon alfa induction hcv combination therapy
US6923966B2 (en) 1999-04-08 2005-08-02 Schering Corporation Melanoma therapy
JP4982019B2 (ja) 1999-07-22 2012-07-25 セルメド オンコロジー （ユーエスエイ）， インコーポレイテッド 酵素によって触媒される治療活性化
US6566365B1 (en) 1999-11-04 2003-05-20 Biochem Pharma Inc. Method for the treatment of Flaviviridea viral infection using nucleoside analogues
US6495677B1 (en) 2000-02-15 2002-12-17 Kanda S. Ramasamy Nucleoside compounds
PL364995A1 (en) 2000-02-18 2004-12-27 Shire Biochem Inc. Method for the treatment or prevention of flavivirus
AU2001259068A1 (en) 2000-04-13 2001-10-30 Pharmasset, Ltd. 3'-or 2'-hydroxymethyl substituted nucleoside derivatives for treatment of hepatitis virus infections
US6924270B2 (en) 2000-04-20 2005-08-02 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
US6787526B1 (en) 2000-05-26 2004-09-07 Idenix Pharmaceuticals, Inc. Methods of treating hepatitis delta virus infection with β-L-2′-deoxy-nucleosides
JP2004513070A (ja) 2000-05-26 2004-04-30 イデニクス（ケイマン）リミテツド β−Ｌ−２’−デオキシヌクレオシドを用いたデルタ型肝炎ウイルス感染の処置方法
EP1294735A2 (en) 2000-05-26 2003-03-26 Novirio Pharmaceuticals Limited Methods and compositions for treating flaviviruses and pestiviruses
MY141594A (en) 2000-06-15 2010-05-14 Novirio Pharmaceuticals Ltd 3'-PRODRUGS OF 2'-DEOXY-ß-L-NUCLEOSIDES
US6815542B2 (en) 2000-06-16 2004-11-09 Ribapharm, Inc. Nucleoside compounds and uses thereof
UA72612C2 (en) 2000-07-06 2005-03-15 Pyrido[2.3-d]pyrimidine and pyrimido[4.5-d]pyrimidine nucleoside analogues, prodrugs and method for inhibiting growth of neoplastic cells
CN1291994C (zh) 2000-07-21 2006-12-27 吉里德科学公司 核苷酸膦酸酯类似物前药及其筛选和制备方法
AR029851A1 (es) 2000-07-21 2003-07-16 Dendreon Corp Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c
AR039558A1 (es) 2000-08-21 2005-02-23 Inspire Pharmaceuticals Inc Composiciones y metodo para el tratamiento de glaucoma o hipertension ocular
US20030008841A1 (en) 2000-08-30 2003-01-09 Rene Devos Anti-HCV nucleoside derivatives
CN1516599A (zh) 2000-10-18 2004-07-28 ���鹫˾ 病毒唑-聚乙二醇化干扰素α联合治疗慢性传染性丙型肝炎的方法
KR101195019B1 (ko) 2000-10-18 2012-10-29 파마셋 인코포레이티드 바이러스 감염 및 비정상적인 세포 증식의 치료를 위한 변형된 뉴클레오시드
WO2002048165A2 (en) 2000-12-15 2002-06-20 Pharmasset Ltd. Antiviral agents for treatment of flaviviridae infections
US7105499B2 (en) 2001-01-22 2006-09-12 Merck & Co., Inc. Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
EP2399588B1 (en) 2001-01-22 2020-04-29 Merck Sharp & Dohme Corp. Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
GB0112617D0 (en) 2001-05-23 2001-07-18 Hoffmann La Roche Antiviral nucleoside derivatives
GB0114286D0 (en) 2001-06-12 2001-08-01 Hoffmann La Roche Nucleoside Derivatives
JP2004534830A (ja) 2001-06-21 2004-11-18 グラクソ　グループ　リミテッド Ｈｃｖにおけるヌクレオシド化合物
EP1404704B9 (en) 2001-07-11 2008-02-20 Vertex Pharmaceuticals Incorporated Bridged bicyclic serine protease inhibitors
EP2335700A1 (en) 2001-07-25 2011-06-22 Boehringer Ingelheim (Canada) Ltd. Hepatitis C virus polymerase inhibitors with a heterobicylic structure
WO2003024461A1 (en) 2001-09-20 2003-03-27 Schering Corporation Hcv combination therapy
US7138376B2 (en) 2001-09-28 2006-11-21 Idenix Pharmaceuticals, Inc. Methods and compositions for treating hepatitis C virus using 4'-modified nucleosides
US7259163B2 (en) 2001-11-02 2007-08-21 Glaxo Group Limited 4-(6-membered)-heteroaryl acyl pyrrolidine derivatives as HCV inhibitors
EP1569652A4 (en) 2001-12-14 2008-07-02 Pharmasset Inc NUCLEOSIDES N SP 4 / SP-ACYLCYTOSINES FOR THE TREATMENT OF VIRAL INFECTIONS
WO2003051899A1 (en) 2001-12-17 2003-06-26 Ribapharm Inc. Deazapurine nucleoside libraries and compounds
US20030153744A1 (en) 2001-12-21 2003-08-14 Micrologix Biotech Inc. Anti-viral 7-deaza L-nucleosides
WO2003062256A1 (en) 2002-01-17 2003-07-31 Ribapharm Inc. 2'-beta-modified-6-substituted adenosine analogs and their use as antiviral agents
US6642204B2 (en) 2002-02-01 2003-11-04 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
AU2003209045B2 (en) 2002-02-13 2006-12-14 Isis Pharmaceuticals, Inc. Methods of inhibiting orthopoxvirus replication with nucleoside compounds
EP1485395A4 (en) 2002-02-28 2011-04-13 Biota Scient Management NUCLEOTIDE MIMETICS AND PRODRUGS THEREOF
CA2477795A1 (en) 2002-02-28 2003-09-12 Kandasamy Sakthivel Nucleoside 5'-monophosphate mimics and their prodrugs
US20040014108A1 (en) 2002-05-24 2004-01-22 Eldrup Anne B. Oligonucleotides having modified nucleoside units
US7449488B2 (en) 2002-06-04 2008-11-11 Schering Corporation Pyrazolopyrimidines as protein kinase inhibitors
AU2003248708A1 (en) 2002-06-17 2003-12-31 Isis Pharmaceuticals, Inc. Oligomeric compounds that include carbocyclic nucleosides and their use in gene modulation
WO2003105770A2 (en) 2002-06-17 2003-12-24 Merck & Co., Inc. Carbocyclic nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
CA2488534A1 (en) 2002-06-21 2003-12-31 Merck & Co., Inc. Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
US20060234962A1 (en) 2002-06-27 2006-10-19 Olsen David B Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
JP5087211B2 (ja) 2002-06-28 2012-12-05 イデニクス（ケイマン）リミテツド フラビウィルス感染治療のための２′および３′−ヌクレオシドプロドラッグ
MXPA04012802A (es) 2002-06-28 2005-04-19 Idenix Cayman Ltd Ester 2'-c-metil-3'-o-l-valina de ribofuranosil-citidina para el tratamiento de infecciones por flaviviridae.
CN100348607C (zh) 2002-06-28 2007-11-14 埃迪尼克斯(开曼)有限公司 用于治疗黄病毒科病毒感染的2’和3’－核苷前药
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
MXPA05000020A (es) 2002-07-01 2005-12-05 Pharmacia & Upjohn Co Llc Inhibidores de polimerasa ns5b de la infeccion del virus de la hepatitis c (hcv).
EP1525183A1 (en) 2002-07-01 2005-04-27 Pharmacia & Upjohn Company LLC Inhibitors of hcv ns5b polymerase
US6973905B2 (en) 2002-07-01 2005-12-13 Cinetic Automation Corporation Valve lash adjustment apparatus and method
WO2004007512A2 (en) 2002-07-16 2004-01-22 Merck & Co., Inc. Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
AU2003256619A1 (en) 2002-07-24 2004-02-09 Isis Pharmaceuticals, Inc. Pyrrolopyrimidine thionucleoside analogs as antivirals
CA2493816A1 (en) 2002-07-24 2004-01-29 Ptc Therapeutics, Inc. Use of nucleoside compounds for nonsense suppression and the treatment of genetic diseases
KR20050037559A (ko) 2002-07-25 2005-04-22 마이크로로직스 바이오테크, 인코포레이티드 항바이러스성 ７-데아자 ｄ-뉴클레오시드 및 그의 용도
TWI244393B (en) 2002-08-06 2005-12-01 Idenix Pharmaceuticals Inc Crystalline and amorphous forms of beta-L-2'-deoxythymidine
US7183302B2 (en) 2002-08-12 2007-02-27 Bristol-Myers Squibb Company Iminothiazolidinones as inhibitors of HCV replication
KR100855907B1 (ko) 2002-09-13 2008-09-02 노파르티스 아게 내성 ＨＢＶ 균주 치료용 β-Ｌ-2'-데옥시뉴클레오시드 및병용 요법
US20050215614A1 (en) 2002-10-15 2005-09-29 Rigel Pharmaceuticals, Inc. Substituted indoles and their use as hcv inhibitors
US20040229840A1 (en) 2002-10-29 2004-11-18 Balkrishen Bhat Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
CA2504344A1 (en) 2002-11-01 2004-05-21 Viropharma Incorporated Benzofuran compounds, compositions and methods for treatment and prophylaxis of hepatitis c viral infections and associated diseases
AU2003287502B2 (en) 2002-11-05 2010-12-09 Isis Pharmaceuticals, Inc. Compositions comprising alternating 2'-modified nucleosides for use in gene modulation
AU2003291753B2 (en) 2002-11-05 2010-07-08 Isis Pharmaceuticals, Inc. Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
US7824851B2 (en) 2002-11-15 2010-11-02 Idenix Pharmaceuticals, Inc. 2′-branched nucleosides and Flaviviridae mutation
TWI332507B (en) 2002-11-19 2010-11-01 Hoffmann La Roche Antiviral nucleoside derivatives
US7223785B2 (en) 2003-01-22 2007-05-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
WO2004080466A1 (en) 2003-03-07 2004-09-23 Ribapharm Inc. Cytidine analogs and methods of use
WO2004094452A2 (en) 2003-04-16 2004-11-04 Bristol-Myers Squibb Company Macrocyclic isoquinoline peptide inhibitors of hepatitis c virus
EP1617848A2 (en) 2003-04-25 2006-01-25 Gilead Sciences, Inc. Anti-cancer phosphonate conjugates
WO2005002626A2 (en) 2003-04-25 2005-01-13 Gilead Sciences, Inc. Therapeutic phosphonate compounds
US7452901B2 (en) 2003-04-25 2008-11-18 Gilead Sciences, Inc. Anti-cancer phosphonate analogs
US20050261237A1 (en) 2003-04-25 2005-11-24 Boojamra Constantine G Nucleoside phosphonate analogs
US7470724B2 (en) 2003-04-25 2008-12-30 Gilead Sciences, Inc. Phosphonate compounds having immuno-modulatory activity
WO2004096286A2 (en) 2003-04-25 2004-11-11 Gilead Sciences, Inc. Antiviral phosphonate analogs
US7407965B2 (en) 2003-04-25 2008-08-05 Gilead Sciences, Inc. Phosphonate analogs for treating metabolic diseases
US20040259934A1 (en) 2003-05-01 2004-12-23 Olsen David B. Inhibiting Coronaviridae viral replication and treating Coronaviridae viral infection with nucleoside compounds
EP1656093A2 (en) 2003-05-14 2006-05-17 Idenix (Cayman) Limited Nucleosides for treatment of infection by corona viruses, toga viruses and picorna viruses
US20040229839A1 (en) 2003-05-14 2004-11-18 Biocryst Pharmaceuticals, Inc. Substituted nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases
PT1633766T (pt) 2003-05-30 2019-06-04 Gilead Pharmasset Llc Análogos de nucleósido fluorado modificado
GB0317009D0 (en) 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
ATE478886T1 (de) 2003-07-25 2010-09-15 Idenix Pharmaceuticals Inc Purin nucleoside für die behandlung von durch flavividrae verursachten krankheiten, einschliesslich hepatitis c
CN1863813B (zh) 2003-08-27 2011-03-30 生物区科学管理控股有限公司 作为治疗剂的三环核苷或核苷酸
JP5379347B2 (ja) 2003-09-18 2013-12-25 アイシス ファーマシューティカルズ， インコーポレーテッド ４’−チオヌクレオシドおよびオリゴマー化合物
US20050119189A1 (en) 2003-09-18 2005-06-02 Cottrell Kevin M. Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
US20050148534A1 (en) 2003-09-22 2005-07-07 Castellino Angelo J. Small molecule compositions and methods for increasing drug efficiency using compositions thereof
CA2542588A1 (en) 2003-10-14 2005-04-28 Lyco Manufacturing, Inc. High speed food product peeling or cleaning machine and method
PL1677827T3 (pl) 2003-10-27 2009-06-30 Vertex Pharma Połączenia do leczenia HCV
US7026339B2 (en) 2003-11-07 2006-04-11 Fan Yang Inhibitors of HCV NS5B polymerase
TW200528459A (en) 2004-01-06 2005-09-01 Achillion Pharmaceuticals Inc Azabenzofuran substituted thioureas; inhibitors of viral replication
CA2557075A1 (en) 2004-02-25 2005-09-09 Government Of The United States Of America, As Represented By The Secret Ary, Department Of Health And Human Services Office Of Technology Transf Methylation inhibitor compounds
EP1745154B1 (en) 2004-05-07 2012-08-01 Celera Corporation Genetic polymorphisms associated with liver fibrosis methods of detection and uses thereof
US8394947B2 (en) 2004-06-03 2013-03-12 Isis Pharmaceuticals, Inc. Positionally modified siRNA constructs
WO2005121634A1 (ja) 2004-06-08 2005-12-22 Tokyo Gas Co., Ltd. ガス吸着容器
WO2005123087A2 (en) 2004-06-15 2005-12-29 Merck & Co., Inc. C-purine nucleoside analogs as inhibitors of rna-dependent rna viral polymerase
RU2007102281A (ru) 2004-06-23 2008-07-27 Айденикс (Кайман) Лимитед (Ky) 5-аза-7-деазапуриновые производные для лечения заболеваний, связанных с flaviviridae
CA2571079A1 (en) 2004-06-24 2006-02-02 Merck & Co., Inc. Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection
JP5078612B2 (ja) 2004-07-21 2012-11-21 ギリアド ファーマセット エルエルシー アルキル置換された２−デオキシ−２−フルオロ−ｄ−リボフラノシルピリミジン類及びプリン類及びそれらの誘導体の調製
CN101023094B (zh) 2004-07-21 2011-05-18 法莫赛特股份有限公司 烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
ES2363160T3 (es) 2004-07-27 2011-07-22 Gilead Sciences, Inc. Conjugados de fosfonato nucelosidico como agentes anti-vih.
US7348425B2 (en) 2004-08-09 2008-03-25 Bristol-Myers Squibb Company Inhibitors of HCV replication
US7153848B2 (en) 2004-08-09 2006-12-26 Bristol-Myers Squibb Company Inhibitors of HCV replication
RU2007110531A (ru) 2004-08-23 2008-09-27 Ф.Хоффманн-Ля Рош Аг (Ch) Гетероциклические противовирусные соединения
JP2008510748A (ja) 2004-08-23 2008-04-10 エフ．ホフマン−ラ ロシュ アーゲー 抗ウイルス４’−アジド−ヌクレオシド
WO2006029081A2 (en) 2004-09-02 2006-03-16 Neopharm, Inc. Nucleoside-lipid conjugates, their method of preparation and uses thereof
WO2006031725A2 (en) 2004-09-14 2006-03-23 Pharmasset, Inc. Preparation of 2'­fluoro-2'- alkyl- substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives
RU2007115419A (ru) 2004-09-24 2008-10-27 Айденикс (Кайман) Лимитед (Ky) Способы и композиции для лечения флавивирусов, пестивирусов и гепацивируса
TW200626157A (en) 2004-09-30 2006-08-01 Tibotec Pharm Ltd HCV inhibiting bi-cyclic pyrimidines
WO2006065335A2 (en) 2004-10-21 2006-06-22 Merck & Co., Inc. Fluorinated pyrrolo[2,3-d]pyrimidine nucleosides for the treatment of rna-dependent rna viral infection
CN101166750A (zh) 2004-10-29 2008-04-23 拜奥克里斯特制药公司 治疗用呋喃并嘧啶类化合物和噻吩并嘧啶类化合物
US20060110724A1 (en) 2004-11-19 2006-05-25 Burkhardt William Iii Quantitative real-time assay for noroviruses and enteroviruses with built in quality control standard
EP1674104A1 (en) 2004-12-24 2006-06-28 Institut National De La Sante Et De La Recherche Medicale (Inserm) Uridine derivatives as antiviral drugs against a flaviviridae, especially HCV
WO2006093801A1 (en) 2005-02-25 2006-09-08 Abbott Laboratories Thiadiazine derivatives useful as anti-infective agents
CN101128474A (zh) 2005-02-28 2008-02-20 健亚生物科技公司 用于治疗病毒感染的三环核苷前药
ATE517897T1 (de) 2005-03-25 2011-08-15 Tibotec Pharm Ltd Heterobicyclische inhibitoren von hvc
WO2006116557A1 (en) 2005-04-25 2006-11-02 Genelabs Technologies, Inc. Nucleoside compounds for treating viral infections
WO2006121820A1 (en) 2005-05-05 2006-11-16 Valeant Research & Development Phosphoramidate prodrugs for treatment of viral infection
AR056347A1 (es) 2005-05-12 2007-10-03 Tibotec Pharm Ltd Uso de compuestos de pteridina para fabricar medicamentos y composiciones farmaceuticas
US20060276405A1 (en) 2005-06-02 2006-12-07 Schering Corporation Methods for treating hepatitis C
US8143288B2 (en) 2005-06-06 2012-03-27 Bristol-Myers Squibb Company Inhibitors of HCV replication
US20060293752A1 (en) 2005-06-27 2006-12-28 Missoum Moumene Intervertebral disc prosthesis and associated methods
SG166791A1 (en) 2005-07-25 2010-12-29 Intermune Inc Novel macrocyclic inhibitors of hepatitis c virus replication
TWI393723B (zh) 2005-07-29 2013-04-21 Tibotec Pharm Ltd Ｃ型肝炎病毒之大環抑制劑（九）
EP1915585A2 (en) 2005-07-29 2008-04-30 Automotive Systems Laboratory Inc. Magnetic crash sensor
ES2373685T3 (es) 2005-07-29 2012-02-07 Tibotec Pharmaceuticals Inhibidores macrocíclicos del virus de la hepatitis c.
PE20070211A1 (es) 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c
CA2617096C (en) 2005-07-29 2013-12-24 Tibotec Pharmaceuticals Ltd. Macrocyclic inhibitors of hepatitis c virus
TWI383980B (zh) 2005-07-29 2013-02-01 Tibotec Pharm Ltd Ｃ型肝炎病毒之大環抑制劑
CA2618335C (en) 2005-08-15 2015-03-31 F.Hoffmann-La Roche Ag Antiviral phosphoramidates of 4'-substituted pronucleotides
US8569478B2 (en) 2005-09-26 2013-10-29 Gilead Pharmasset Llc Modified 4′-nucleosides as antiviral agents
JP5116687B2 (ja) 2005-11-02 2013-01-09 バイエル・ファルマ・アクチェンゲゼルシャフト がんおよび他の過剰増殖性疾患の処置のためのピロロ［２，１−ｆ］［１，２，４］トリアジン−４−イルアミンＩＧＦ−１Ｒキナーゼ阻害剤
NZ568909A (en) 2005-12-09 2011-10-28 Hoffmann La Roche Antiviral 4-fluoro-4-methyl nucleoside prodrugs
RU2008128452A (ru) 2005-12-12 2010-01-20 Дженелабс Текнолоджис, Инк. (Us) Соединения n-(6-членных арил)-амидов, фармацевтическая композиция с противовирусной активностью на их основе, способ лечения или профилактики вирусной инфекции с их помощью и способ их получения
RU2467007C2 (ru) 2005-12-21 2012-11-20 Эбботт Лэборетриз Производные [1,8]нафтиридина, полезные в качестве ингибиторов репликации вируса hcv
AU2006330924B2 (en) 2005-12-21 2012-03-15 Abbvie Inc. Anti-viral compounds
JP2009526850A (ja) 2006-02-14 2009-07-23 メルク エンド カムパニー インコーポレーテッド Ｒｎａ依存性ｒｎａウイルス感染を治療するためのヌクレオシドアリールホスホルアミデート
EP1987030B1 (en) 2006-02-17 2011-11-09 Pfizer Limited 3 -deazapurine derivatives as tlr7 modulators
US8895531B2 (en) 2006-03-23 2014-11-25 Rfs Pharma Llc 2′-fluoronucleoside phosphonates as antiviral agents
US7521442B2 (en) 2006-05-25 2009-04-21 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
JP5205370B2 (ja) 2006-05-25 2013-06-05 ブリストル−マイヤーズ スクイブ カンパニー シクロプロピル縮合インドロベンゾアゼピンｈｃｖｎｓ５ｂ阻害剤
TWI399377B (zh) 2006-07-07 2013-06-21 Gilead Sciences Inc 類鐸受體７之調節劑
DE602007004220D1 (de) 2006-07-07 2010-02-25 Leuven K U Res & Dev Neue pyridazinverbindung und ihre verwendung
US20090227491A1 (en) 2006-07-07 2009-09-10 Gilead Sciences, Inc. Antiviral phosphinate compounds
EP2049506B2 (en) 2006-07-07 2024-05-08 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics
US8329159B2 (en) 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7759495B2 (en) 2006-08-11 2010-07-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7659270B2 (en) 2006-08-11 2010-02-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8303944B2 (en) 2006-08-11 2012-11-06 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
ES2429290T3 (es) 2006-10-10 2013-11-14 Gilead Pharmasset Llc Preparación de nucleósidos de ribofuranosilpirimidinas
PL216525B1 (pl) 2006-10-17 2014-04-30 Ct Badań Molekularnych I Makromolekularnych Polskiej Akademii Nauk 5'-O-[(N-acylo)amidoditiofosforano] nukleozydy oraz sposób wytwarzania 5'-O-[(N-acylo)amidofosforano]-,5'-O-[(N-acylo)amidotiofosforano]-, 5'-O-[(N-acylo)amidoditiofosforano]nukleozydów
CA2672613A1 (en) 2006-12-20 2008-07-03 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Nucleoside cyclic phosphoramidates for the treatment of rna-dependent rna viral infection
US7951789B2 (en) 2006-12-28 2011-05-31 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
WO2008085508A2 (en) 2007-01-05 2008-07-17 Merck & Co., Inc. Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
ATE548044T1 (de) * 2007-05-04 2012-03-15 Vertex Pharma Kombinationstherapie zur behandlung von hiv- infektionen
US7741347B2 (en) 2007-05-17 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
GB0709791D0 (en) 2007-05-22 2007-06-27 Angeletti P Ist Richerche Bio Antiviral agents
US20100160335A1 (en) 2007-06-19 2010-06-24 Kyorin Pharmaceutical Co., Ltd. Pyridazinone derivative and pde inhibitor containing the same as active ingredient
US7968544B2 (en) 2007-06-29 2011-06-28 Gilead Sciences, Inc. Modulators of toll-like receptor 7
KR20100038417A (ko) 2007-06-29 2010-04-14 길리애드 사이언시즈, 인코포레이티드 항바이러스 화합물
JP5465666B2 (ja) 2007-06-29 2014-04-09 ギリアード サイエンシーズ， インコーポレイテッド 抗ウイルス化合物
UA99466C2 (en) 2007-07-06 2012-08-27 Гилиад Сайенсиз, Инк. Crystalline pyridazine compound
CN101108870A (zh) 2007-08-03 2008-01-23 冷一欣 核苷磷酸酯类化合物及制备方法和应用
US8629171B2 (en) 2007-08-08 2014-01-14 Bristol-Myers Squibb Company Crystalline form of methyl ((1S)-1-((25)-2-(5-(4'-(2-((25)-1((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate dihydrochloride salt
US7728027B2 (en) 2007-08-08 2010-06-01 Bristol-Myers Squibb Company Process for synthesizing compounds useful for treating hepatitis C
CA2699280A1 (en) 2007-09-14 2009-03-26 Schering Corporation Method of treating hepatitis c patients
JO2778B1 (en) 2007-10-16 2014-03-15 ايساي انك Certain vehicles, installations and methods
DE102007052070A1 (de) 2007-10-30 2009-05-07 Tiefenbacher Pharmachemikalien Alfred E. Tiefenbacher Gmbh & Co. Kg Candesartancilexetil
JP5238939B2 (ja) 2007-11-07 2013-07-17 三菱化学株式会社 長繊維強化複合樹脂組成物および成形品
EA201001128A1 (ru) 2008-01-11 2011-02-28 Антариа Лимитед Фотозащитные от уф-излучения композиции, прозрачные в видимой области света
DK2250163T3 (da) 2008-02-12 2012-07-16 Bristol Myers Squibb Co Hepatitis C-virusinhibitorer
EP2242752B1 (en) 2008-02-13 2012-08-08 Bristol-Myers Squibb Company Imidazolyl biphenyl imidazoles as hepatitis c virus inhibitors
US8147818B2 (en) 2008-02-13 2012-04-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7704992B2 (en) 2008-02-13 2010-04-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8227431B2 (en) 2008-03-17 2012-07-24 Hetero Drugs Limited Nucleoside derivatives
US20110269814A1 (en) 2008-03-26 2011-11-03 Alnylam Pharamaceuticals, Inc. 2'-f modified rna interference agents
EP2282762A2 (en) 2008-04-15 2011-02-16 Intermune, Inc. Novel macrocyclic inhibitors of hepatitis c virus replication
EP3042660A3 (en) 2008-04-15 2016-10-26 RFS Pharma, LLC. Nucleoside derivatives for treatment of caliciviridae infections, including norovirus infections
BRPI0910455B8 (pt) 2008-04-23 2021-05-25 Gilead Sciences Inc análogos de carba-nucleosídeo 1’-substituído para tratamento antiviral e composição farmacêutica que os compreende
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
JP2011527331A (ja) 2008-07-10 2011-10-27 プロシディオン・リミテッド ピペリジニルｇｐｃｒ作動薬
US7906655B2 (en) 2008-08-07 2011-03-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7921612B2 (en) 2008-08-31 2011-04-12 United Construction Products, Inc. Method and device for supporting a structure
US8383094B2 (en) 2008-10-01 2013-02-26 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
DE102008057284A1 (de) 2008-11-14 2010-05-20 Ratiopharm Gmbh Tabletten enthaltend Lenalidomid und Adhäsionsverstärker
US8729077B2 (en) 2008-11-28 2014-05-20 Glaxosmithkline Llc Anti-viral compounds, compositions, and methods of use
BRPI0922364A2 (pt) 2008-12-03 2017-08-29 Presidio Pharmaceuticals Inc Composto, composição farmacêutica e uso de um composto
PT2373172E (pt) 2008-12-03 2013-10-21 Presidio Pharmaceuticals Inc Inibidores de ns5a de hcv
TW201639852A (zh) 2008-12-09 2016-11-16 吉李德科學股份有限公司 用於製備可用作類鐸受體調節劑之化合物的中間體化合物
TW201031675A (en) 2008-12-23 2010-09-01 Pharmasset Inc Synthesis of purine nucleosides
EP2376088B1 (en) 2008-12-23 2017-02-22 Gilead Pharmasset LLC 6-O-Substituted-2-amino-purine nucleoside phosphoramidates
EP2376514A2 (en) 2008-12-23 2011-10-19 Pharmasset, Inc. Nucleoside analogs
MX2011007194A (es) 2009-01-07 2013-07-12 Scynexis Inc Combinacion de un derivado ciclosporina y nucleosidos para tratar virus de hepatitis c (vhc).
CN102348712A (zh) 2009-01-09 2012-02-08 卡迪夫大学学院顾问有限公司 用于治疗病毒感染的鸟苷核苷类化合物的磷酰胺酯衍生物
WO2010091413A1 (en) 2009-02-09 2010-08-12 Enanta Pharmaceuticals, Inc. Linked dibenzimidazole derivatives
WO2010096462A1 (en) 2009-02-17 2010-08-26 Enanta Pharmaceuticals, Inc Linked diimidazole derivatives
TWI438200B (zh) 2009-02-17 2014-05-21 必治妥美雅史谷比公司 Ｃ型肝炎病毒抑制劑
WO2010094977A1 (en) 2009-02-23 2010-08-26 Arrow Therapeutics Limited Novel biphenyl compounds useful for the treatment of hepatitis c
WO2010096777A1 (en) 2009-02-23 2010-08-26 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
SG10201400235PA (en) 2009-02-27 2014-07-30 Enanta Pharm Inc Hepatitis c virus inhibitors
JP2012521359A (ja) 2009-03-20 2012-09-13 アリオス バイオファーマ インク． 置換されたヌクレオシドアナログおよびヌクレオチドアナログ
ES2573088T3 (es) 2009-03-27 2016-06-06 Merck Sharp & Dohme Corp. Inhibidores de la replicación del virus de la hepatitis C
WO2010111673A1 (en) 2009-03-27 2010-09-30 Presidio Pharmaceuticals, Inc. Substituted bicyclic hcv inhibitors
US9150554B2 (en) 2009-03-27 2015-10-06 Presidio Pharmaceuticals, Inc. Fused ring inhibitors of hepatitis C
TWI476190B (zh) 2009-03-30 2015-03-11 必治妥美雅史谷比公司 Ｃ型肝炎病毒抑制劑
US8796466B2 (en) 2009-03-30 2014-08-05 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
DE102009015702A1 (de) 2009-03-31 2010-10-07 Ratiopharm Gmbh Tabletten enthaltend Dapoxetin und Trockenverarbeitungsverfahren zu deren Herstellung
TW201038559A (en) 2009-04-09 2010-11-01 Bristol Myers Squibb Co Hepatitis C virus inhibitors
US8143414B2 (en) 2009-04-13 2012-03-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
SG175144A1 (en) 2009-04-15 2011-11-28 Abbott Lab Anti-viral compounds
EP2421855A1 (en) 2009-04-24 2012-02-29 Tibotec Pharmaceuticals Diaryl ethers
EP2430015B1 (en) 2009-05-12 2015-06-17 Merck Sharp & Dohme Corp. Fused tricyclic compounds useful for the treatment of viral diseases
DK2430014T3 (en) * 2009-05-13 2015-11-30 Gilead Pharmasset Llc Anti-viral compounds
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI598358B (zh) 2009-05-20 2017-09-11 基利法瑪席特有限責任公司 核苷磷醯胺
US8138215B2 (en) 2009-05-29 2012-03-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2010138790A1 (en) 2009-05-29 2010-12-02 Schering Corporation Antiviral compounds composed of three aligned aryl moieties to treat diseases such as hepatitis c
CA2763140A1 (en) 2009-05-29 2010-12-02 Schering Corporation Antiviral compounds composed of three linked aryl moieties to treat diseases such as hepatitis c
US8211928B2 (en) 2009-05-29 2012-07-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN102333772B (zh) 2009-06-11 2013-12-11 雅培制药有限公司 抗病毒化合物
WO2010148006A1 (en) 2009-06-16 2010-12-23 Enanta Pharmaceuticals, Inc. Hepatitis c virus inhibitors
US8221737B2 (en) 2009-06-16 2012-07-17 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
WO2011004276A1 (en) 2009-07-06 2011-01-13 Pfizer Limited Hepatitis c virus inhibitors
JP5542910B2 (ja) 2009-07-13 2014-07-09 株式会社メニコン 広範囲の抗菌活性を有するコーティング剤としてのキトサンヒドロゲル誘導体
IN2012DN00999A (pt) 2009-07-16 2015-04-10 Vertex Pharma
EP2467144A1 (en) 2009-07-24 2012-06-27 ViroLogik GmbH Combination of proteasome inhibitors and anti-hepatitis medication for treating hepatitis
WO2011015658A1 (en) 2009-08-07 2011-02-10 Tibotec Pharmaceuticals Bis-benzimidazole derivatives as hepatitis c virus inhibitors
WO2011015657A1 (en) 2009-08-07 2011-02-10 Tibotec Pharmaceuticals Phenyl ethynyl derivatives as hepatitis c virus inhibitors
FR2949465B1 (fr) 2009-09-01 2011-08-12 Pf Medicament Derives chromones, leur procede de preparation et leurs applications therapeutiques
CA2772484A1 (en) 2009-09-03 2011-03-10 Tibotec Pharmaceuticals Bis-benzimidazole derivatives
US8344155B2 (en) 2009-09-04 2013-01-01 Glaxosmith Kline Llc Chemical compounds
EP2475254A4 (en) 2009-09-11 2013-05-22 Enanta Pharm Inc HEPATITIS C-VIRUS HEMMER
EP2475256A4 (en) 2009-09-11 2013-06-05 Enanta Pharm Inc HEPATITIS C-VIRUS HEMMER
ME02656B (me) 2009-09-21 2017-06-20 Gilead Sciences Inc 2' -fluoro supstituisani karba-nukleozidni analozi za antiviralno lečenje
US8415374B2 (en) 2009-10-12 2013-04-09 Bristol-Myers Squibb Company Combinations of hepatitis C virus inhibitors
WO2011050146A1 (en) 2009-10-23 2011-04-28 Glaxosmithkline Llc Chemical compounds
UA108211C2 (uk) 2009-11-04 2015-04-10 Янссен Рід Айрленд Бензімідазолімідазольні похідні
CN102055717B (zh) 2009-11-09 2014-08-13 华为技术有限公司 快速播放的方法、终端及服务器
US20110274648A1 (en) 2009-11-11 2011-11-10 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20110269956A1 (en) 2009-11-11 2011-11-03 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20110281910A1 (en) 2009-11-12 2011-11-17 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
AU2010324871A1 (en) 2009-11-25 2012-06-14 Merck Sharp & Dohme Corp. Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases
US20110137633A1 (en) 2009-12-03 2011-06-09 Abbott Laboratories Anti-viral compounds and methods of identifying the same
US8653070B2 (en) 2009-12-14 2014-02-18 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8377980B2 (en) 2009-12-16 2013-02-19 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2011075607A1 (en) 2009-12-18 2011-06-23 Intermune, Inc. Novel inhibitors of hepatitis c virus replication
MX2012006877A (es) 2009-12-18 2012-08-31 Idenix Pharmaceuticals Inc Inhibidores de virus de hepatitis c de arileno o heteroarileno 5, 5 - fusionado.
MX2012007076A (es) * 2009-12-18 2012-07-20 Boehringer Ingelheim Int Terapia combinada de hcv.
WO2011087740A1 (en) 2009-12-22 2011-07-21 Schering Corporation Fused tricyclic compounds and methods of use thereof for the treatment of viral diseases
WO2011079327A1 (en) 2009-12-24 2011-06-30 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of flavivirus infections
US8362020B2 (en) 2009-12-30 2013-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
AP3576A (en) * 2010-01-15 2016-02-08 Gilead Sciences Inc Inhibitors of flaviviridae viruses
WO2011091446A1 (en) 2010-01-22 2011-07-28 Glaxosmithkline Llc Chemical compounds
EP2545060B1 (en) 2010-03-09 2015-11-25 Merck Sharp & Dohme Corp. Fused tricyclic silyl compounds and methods of use thereof for the treatment of viral diseases
US8563530B2 (en) 2010-03-31 2013-10-22 Gilead Pharmassel LLC Purine nucleoside phosphoramidate
UY33312A (es) 2010-03-31 2011-10-31 Pharmasset Inc Fosforamidato de nucleosido de purina
UY33311A (es) 2010-03-31 2011-10-31 Pharmasset Inc Fosforamidatos de nucleosidos
BR112012026124A2 (pt) 2010-04-13 2016-11-22 Hoffmann La Roche previsão de resposta virológica precoce no tratamento de hcv
US20110312996A1 (en) 2010-05-17 2011-12-22 Intermune, Inc. Novel inhibitors of hepatitis c virus replication
TW201201815A (en) 2010-05-28 2012-01-16 Gilead Sciences Inc 1'-substituted-carba-nucleoside prodrugs for antiviral treatment
TW201211047A (en) 2010-06-10 2012-03-16 Gilead Sciences Inc Methods for treating HCV
KR20200052384A (ko) 2010-07-19 2020-05-14 길리애드 사이언시즈, 인코포레이티드 부분입체 이성질성으로 순수한 포스포라미데이트 전구약물의 제조 방법
EP2616461A4 (en) 2010-08-26 2014-03-26 Rfs Pharma Llc POWERFUL AND SELECTIVE INHIBITORS OF HEPATITIS C VIRUS
CA2807496C (en) 2010-09-20 2019-01-22 Gilead Sciences, Inc. 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
KR20140001879A (ko) 2010-09-29 2014-01-07 머크 샤프 앤드 돔 코포레이션 Ｃ형 간염 바이러스 감염을 치료하기 위한 테트라시클릭 인돌 유도체
WO2012048421A1 (en) 2010-10-14 2012-04-19 Boehringer Ingelheim International Gmbh Hepatitis c inhibitor compounds
US20120107278A1 (en) 2010-10-29 2012-05-03 Pharmasset, Inc. Abbreviated hcv therapy for hcv infected patients with il28b c/c genotype
KR101835474B1 (ko) 2010-11-17 2018-03-08 길리애드 파마셋 엘엘씨 항바이러스 화합물
US8841275B2 (en) 2010-11-30 2014-09-23 Gilead Pharmasset Llc 2′-spiro-nucleosides and derivatives thereof useful for treating hepatitis C virus and dengue virus infections
NZ613370A (en) 2010-12-20 2015-05-29 Gilead Sciences Inc Combinations for treating hcv
WO2012087976A2 (en) 2010-12-21 2012-06-28 Intermune, Inc. Novel inhibitors of hepatitis c virus replication
US8655250B2 (en) 2011-03-31 2014-02-18 Xerox Corporation Apparatus and method for marking material fix level control in a printing apparatus
CN103491966A (zh) 2011-03-31 2014-01-01 弗·哈夫曼-拉罗切有限公司 Hcv治疗的选择
US20140113958A1 (en) 2011-06-30 2014-04-24 Stella Aps HCV Combination Therapy
SI2709613T2 (sl) 2011-09-16 2020-12-31 Gilead Pharmasset LLC c/o Gilead Sciences, Inc. Postopki za zdravljenje HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
CA2811250C (en) 2011-10-21 2015-08-11 Abbvie Inc. Methods for treating hcv
GB2506086A (en) 2011-10-21 2014-03-19 Abbvie Inc Methods for treating HCV comprising at least two direct acting antiviral agent, ribavirin but not interferon
US20130109647A1 (en) 2011-10-31 2013-05-02 Gilead Pharmasset Llc Methods and compositions for treating hepatitis c virus
AU2012332827A1 (en) 2011-10-31 2014-05-15 Gilead Pharmasset Llc Methods and compositions for treating hepatitis C virus
SI2907816T1 (sl) 2011-11-16 2018-10-30 Gilead Pharmasset Llc Kondenzirani imidazolilimidazoli kot protivirusni sestavki
AU2012346217B2 (en) 2011-11-29 2016-02-04 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
JP5781706B2 (ja) 2011-12-29 2015-09-24 アッヴィ・アイルランド・アンリミテッド・カンパニー Ｈｃｖ阻害剤を含む固体組成物
CA2863282A1 (en) 2012-01-13 2013-07-18 Gilead Pharmasset Llc Crystal structure of hcv polymerase complexes and methods of use
US8969588B2 (en) 2012-06-05 2015-03-03 Gilead Pharmasset Llc Solid forms of an antiviral compound
US9056860B2 (en) 2012-06-05 2015-06-16 Gilead Pharmasset Llc Synthesis of antiviral compound
TW201446286A (zh) 2013-01-31 2014-12-16 Gilead Pharmasset Llc 抗病毒化合物之固態分散調製劑
SG11201506021XA (en) 2013-01-31 2015-08-28 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
US20140249101A1 (en) 2013-03-04 2014-09-04 Gilead Pharmasset Llc Methods for treating hepatitis c virus infection
WO2014185995A1 (en) 2013-05-16 2014-11-20 Gilead Pharmasset Llc Hepatitis c treatments with sofosbuvir

Also Published As

Publication number Publication date
MD4589B1 (ro) 2018-08-31
AP2014007575A0 (en) 2012-04-30
AU2012308295A1 (en) 2014-04-17
ME03009B (me) 2018-10-20
CO6930366A2 (es) 2014-04-28
BR112014006324B8 (pt) 2019-02-12
WO2013040492A2 (en) 2013-03-21
MX2014003145A (es) 2014-04-30
US9393256B2 (en) 2016-07-19
US20160354425A1 (en) 2016-12-08
MX354958B (es) 2018-03-27
DE202012013074U1 (de) 2014-10-29
EA026667B9 (ru) 2017-07-31
KR20190075142A (ko) 2019-06-28
SI2709613T1 (en) 2018-01-31
ES2659216T5 (es) 2021-06-09
EA026667B1 (ru) 2017-05-31
CR20140177A (es) 2014-08-18
ECSP14013312A (es) 2014-06-30
JP2017057230A (ja) 2017-03-23
BR112014006324B1 (pt) 2018-12-26
CN104244945B (zh) 2016-08-31
HRP20180237T1 (hr) 2018-03-09
RS56975B1 (sr) 2018-05-31
EP2709613B1 (en) 2017-11-29
IL231515A (en) 2017-05-29
CA2840242C (en) 2019-03-26
HRP20180237T4 (hr) 2020-12-11
CA2840242A1 (en) 2013-03-21
TR201802537T4 (tr) 2018-03-21
MX336580B (es) 2016-01-22
US10456414B2 (en) 2019-10-29
JP6073897B2 (ja) 2017-02-01
KR101991298B1 (ko) 2019-06-21
DK2709613T4 (da) 2020-11-16
EA201490588A1 (ru) 2015-01-30
HK1231378A1 (zh) 2017-12-22
SI2709613T2 (sl) 2020-12-31
DK2709613T3 (en) 2018-02-26
CN104244945A (zh) 2014-12-24
US20170189439A1 (en) 2017-07-06
IL231515A0 (en) 2014-04-30
JP2014526516A (ja) 2014-10-06
LT2709613T (lt) 2018-02-12
PT2709613T (pt) 2018-02-16
JP6220994B2 (ja) 2017-10-25
PL2709613T3 (pl) 2018-05-30
CY1119896T1 (el) 2018-06-27
SG11201400664WA (en) 2014-04-28
MD4589C1 (ro) 2019-03-31
ES2659216T3 (es) 2018-03-14
AU2012308295B2 (en) 2017-10-26
KR20140096029A (ko) 2014-08-04
MD20140035A2 (ro) 2014-08-31
PL2709613T5 (pl) 2020-12-14
CN106166160A (zh) 2016-11-30
DE202012013074U8 (de) 2015-02-19
NZ623396A (en) 2016-07-29
PE20141056A1 (es) 2014-09-05
UA116087C2 (uk) 2018-02-12
US20130243726A1 (en) 2013-09-19
NZ720391A (en) 2017-10-27
EP2709613B2 (en) 2020-08-12
BR112014006324A2 (pt) 2016-06-07
CL2014000630A1 (es) 2014-11-07
WO2013040492A3 (en) 2013-07-25
DE202012013382U1 (de) 2016-08-23
EP2709613A2 (en) 2014-03-26
HUE036588T2 (hu) 2018-07-30

Similar Documents

Publication Publication Date Title
HRP20180237T1 (hr) Metode za liječenje hcv-a
HK1198869A1 (en) Combination treatments for hepatitis c
GB201103499D0 (en) Process
GB201107072D0 (en) Process
ZA201208219B (en) Method for treating wasterwater
HK1209319A1 (en) Methods for treating hepatitis c
GB201101370D0 (en) Process
GB201107073D0 (en) Process
HK1209320A1 (en) Methods for treating hepatitis c
GB201121950D0 (en) Treatment process
GB201103092D0 (en) Process
HK1209040A1 (en) Methods for treating vestibulotoxicity
GB201105523D0 (en) Treatment method
GB201107221D0 (en) Process
AU2013201585B9 (en) Methods for treating HCV
GB201105056D0 (en) Treatment process
GB201108511D0 (en) Process
GB201108345D0 (en) Process
GB201107198D0 (en) Process
GB201107193D0 (en) Process
GB201104762D0 (en) Process
GB201100092D0 (en) Process